Trial reportScientific reports2019
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.
Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening to Improve Survival in AL Amyloidosis
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies.Current drug safety · 2024Pooled it
- Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence.Current cardiology reports · 2026Review
- Two Decades of Light-Chain Amyloidosis: Real-World Trends in Diagnosis, Treatment, and Survival.Journal of hematology · 2026Article
- Reply: Technetium Pyrophosphate Blood Pool Uptake Mistaken for Myocardial Uptake in Light-Chain Amyloidosis: A Dangerous Misinterpretation.JACC. Case reports · 2026Article
- Rare case of young cardiac amyloidosis: difficult diagnostic pathway in routine clinical care.European heart journal. Case reports · 2026Article
- AL Cardiac Amyloidosis Presenting as Grade 3 ATTR Mimicry on Scintigraphy.JACC. Case reports · 2026Article
- Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.American journal of cardiovascular disease · 2026Article
- Temporal and Geographical Disparities in Amyloid and Heart Failure-Related Mortality: An Epidemiological Study 1999-2020.Current cardiology reviews · 2026Article
- Clinical characteristics and prognosis of immunoglobulin light chain amyloidosis patients.Frontiers in medicine · 2026Article
- Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study.Reviews in cardiovascular medicine · 2026Article
- Echocardiographic risk stratification in light chain and transthyretin amyloidosis: a meta-analysis.European heart journal open · 2025Article
- Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.Journal of clinical medicine · 2025Article
- Prognostic Value of Submaximal Cardiopulmonary Exercise Testing in Patients With Cardiac Amyloidosis.Circulation reports · 2025Article
- Multimodality imaging features of systemic amyloidosis: a case report.BMC cardiovascular disorders · 2025Article
- C-reactive protein: the nexus between inflammation and protein misfolding diseases.Frontiers in immunology · 2025Review
- The Prognostic Value of Platelet-to-Lymphocyte Ratio and Tricuspid Regurgitation Velocity in Patients with Light-Chain Myocardial Amyloidosis.Journal of inflammation research · 2025Article
- The myocardial function index (MFI): An integrated measure of cardiac function in AL-cardiomyopathy.International journal of cardiology. Heart & vasculature · 2024Article
- Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.ESC heart failure · 2024Observational
- A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Frontiers in medicine · 2024Review
- Prevalence of transthyretin cardiac amyloidosis in patients with aortic stenosis.American journal of cardiovascular disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiac involvement in systemic amyloidosis (AL) occurs in ~50% of all AL patients. However once symptomatic heart failure develops, therapeutic options are limited thereby conferring a poor overall prognosis. The median survival is <6 months when AL patients are untreated for the underlying plasma cell dyscrasia. We thus sought to identify risk factors of increased mortality in treatment-naïve, AL cardiac amyloidosis with heart failure. Patients with biopsy-proven AL cardiac amyloid, who presented with heart failure and did not received prior AL treatment, were enrolled between 2004-2014, at the initial visit to the Amyloidosis Center at Boston University Medical Center. Routine laboratory tests, physical examination and echocardiography data were collected. There were 165 predominantly white (76.4%), and male (61%) patients, with a mean age of 61.6 ± 9.5 years. Median survival was 10.9 months (95% CI 6.2-14.7). By multivariate analysis increased relative wall thickness (RWT) [HR 6.70; 95% CI 2.45-18.30), older age (HR 1.04; 95% CI 1.01-1.06), higher New York Heart Association (NYHA) functional class (HR 1.50; 95% CI 1.02-2.2), log brain natriuretic peptide (BNP) levels (HR 1.45; 95% CI 1.15-1.81) and C-reactive protein (CRP) levels (HR 1.02; 95% CI 1.00-1.04) were significant predictors for increased mortality. In conclusion, in treatment-naïve, AL cardiac amyloidosis patients with heart failure symptoms who lack these high-risk features may have a better outcome. These findings might allow for better risk stratification although outcomes are still poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.